基于昆的希夫基作为可能的抗糖尿病药物:基于联体的药模拟,3D QSAR,对接和分子动力学模拟研究
Shriram D Ranade1, Shankar G Alegaon1, Nayeem A Khatib2
1Department of Pharmaceutical Chemistry, KLE College of Pharmacy, Belagavi, KLE Academy of Higher education and Research Belagavi - 590010 Karnataka India sgalegaon@gmail.com sgalegaon@klepharm.edu.
这项研究确定了基于林的化基希夫基作为潜在的α-葡萄糖酶抑制剂来控制2型糖尿病. 化合物6b和6c表现出显著的酶抑制,没有显示毒性.
科学领域:
- 药用化学 医学化学
- 计算化学计算化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 2型糖尿病 (T2DM) 的管理需要控制食后高血糖.
- 阿尔法-葡萄糖酶酶抑制剂为T2DM提供了治疗策略.
- 基于诺林的支架正在探索它们作为α-葡萄糖酶抑制剂的潜力.
研究的目的:
- 为了确定负责α-葡萄糖酶抑制的关键药理特征.
- 设计,合成和评估基于林的新型化基希夫基,以检测它们对α-葡萄糖酶和α-氨基酶的抑制潜力.
- 通过计算和体外研究来验证发现.
主要方法:
- 基于体的药模拟和3D定量结构-活性关系 (QSAR) 模型开发.
- 使用光谱技术 (IR,NMR,质谱) 合成和描述基于素的化基希夫基 (化合物6a-6j).
- 在体外酶抑制试验,MTT细胞毒性试验,分子对接,分子动力学模拟,MM/GBSA,DFT计算和ADMET分析.
主要成果:
- 化合物6c表现出强大的α-葡萄糖酶抑制 (IC50:12.95±2.35μM) 和化合物6b (IC50:19.37±0.96μM) 显示出与阿卡相似的活性.
- 抑制动力学揭示了6b和6c化合物的竞争性抑制机制.
- QSAR模型显示出强烈的相关性 (R2 = 0.96),所有合成的化合物在L929细胞系中都是无毒的.
结论:
- 鉴定的药用特征和开发的QSAR模型对于设计有效的α-葡萄糖酶抑制剂至关重要.
- 新型类基化基希夫基,特别是6b和6c化合物,是T2DM治疗的有希望的候选者.
- 综合的计算和体外分析证实了这些化合物的治疗潜力和安全性.
更多相关视频
10:25Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
Published on: November 22, 2024
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
相关概念视频
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Drug Discovery: Overview
The Equilibrium Binding Constant and Binding Strength
